The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TGFb signature at 2 weeks to predict response to preoperative therapy (PT) with bevacizumab (B) and chemotherapy (CT) in early breast cancer (EBC).
Nicole Williams
No relevant relationships to disclose
Vinay Varadan
No relevant relationships to disclose
Aditi Vadodkar
No relevant relationships to disclose
Kristy Miskimen
No relevant relationships to disclose
Hannah L. Gilmore
No relevant relationships to disclose
Nicholas Beckloff
No relevant relationships to disclose
Simone Edelheit
No relevant relationships to disclose
Dhivya Prabhakar
No relevant relationships to disclose
Angel Janevski
No relevant relationships to disclose
Nila Banerjee
No relevant relationships to disclose
Sitharthan Kamalakaran
No relevant relationships to disclose
Maysa M. Abu-Khalaf
Consultant or Advisory Role - Abraxis BioScience
Research Funding - Abraxis BioScience; Genentech
William M. Sikov
No relevant relationships to disclose
Nevenka Dimitrova
No relevant relationships to disclose
Lyndsay Harris
No relevant relationships to disclose